BAYER/NUVELO: BEGINNING A JOINT ADVENTURE

Bayer and Nuvelo have begun enrolling patients for alfimeprase's SONOMA-3 trial. Bayer and Nuvelo have started patient enrollment in a second phase III clinical trial of alfimeprase in central venous catheter occlusion. The trial marks the start of Bayer's involvement in the clinical development of the novel thrombolytic agent following a much-applauded agreement with Nuvelo. However, trials in other indications may prove to be of more benefit to Bayer's shareholders.
Pharmaceutical Business Review